441 related articles for article (PubMed ID: 25947577)
21. Prognostic Value of Maximum Standardized Uptake Value in 68Ga-Somatostatin Receptor Positron Emission Tomography for Neuroendocrine Tumors: A Systematic Review and Meta-analysis.
Lee DY; Kim YI
Clin Nucl Med; 2019 Oct; 44(10):777-783. PubMed ID: 31283601
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic value of [
Choi SJ; Choi SH; Lee DY; Lee JS; Kim DW; Jang JK
Eur Radiol; 2022 Jul; 32(7):4628-4637. PubMed ID: 35092473
[TBL] [Abstract][Full Text] [Related]
23. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
[TBL] [Abstract][Full Text] [Related]
24. Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors.
Opalińska M; Morawiec-Sławek K; Kania-Kuc A; Al Maraih I; Sowa-Staszczak A; Hubalewska-Dydejczyk A
Front Endocrinol (Lausanne); 2022; 13():929391. PubMed ID: 36046793
[TBL] [Abstract][Full Text] [Related]
25. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
26. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
[TBL] [Abstract][Full Text] [Related]
27. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of (68)Ga-DOTANOC PET/CT imaging in a large exclusive population of pancreatic neuroendocrine tumors.
Sharma P; Arora S; Dhull VS; Naswa N; Kumar R; Ammini AC; Bal C
Abdom Imaging; 2015 Feb; 40(2):299-309. PubMed ID: 25134801
[TBL] [Abstract][Full Text] [Related]
29. Dynamic 68Ga-DOTATOC PET/CT and static image in NET patients. Correlation of parameters during PRRT.
Van Binnebeek S; Koole M; Terwinghe C; Baete K; Vanbilloen B; Haustermans K; Clement PM; Bogaerts K; Verbruggen A; Nackaerts K; Van Cutsem E; Verslype C; Mottaghy FM; Deroose CM
Nuklearmedizin; 2016 Jun; 55(3):104-14. PubMed ID: 27056060
[TBL] [Abstract][Full Text] [Related]
30. Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors.
Taïeb D; Garrigue P; Bardiès M; Abdullah AE; Pacak K
PET Clin; 2015 Oct; 10(4):477-86. PubMed ID: 26384594
[TBL] [Abstract][Full Text] [Related]
31. PRRT genomic signature in blood for prediction of
Bodei L; Kidd MS; Singh A; van der Zwan WA; Severi S; Drozdov IA; Cwikla J; Baum RP; Kwekkeboom DJ; Paganelli G; Krenning EP; Modlin IM
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1155-1169. PubMed ID: 29484451
[TBL] [Abstract][Full Text] [Related]
32. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
[TBL] [Abstract][Full Text] [Related]
33. Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors.
Campana D; Ambrosini V; Pezzilli R; Fanti S; Labate AM; Santini D; Ceccarelli C; Nori F; Franchi R; Corinaldesi R; Tomassetti P
J Nucl Med; 2010 Mar; 51(3):353-9. PubMed ID: 20150249
[TBL] [Abstract][Full Text] [Related]
34. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors.
Fani M; Mueller A; Tamma ML; Nicolas G; Rink HR; Cescato R; Reubi JC; Maecke HR
J Nucl Med; 2010 Nov; 51(11):1771-9. PubMed ID: 20956465
[TBL] [Abstract][Full Text] [Related]
35. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
[TBL] [Abstract][Full Text] [Related]
36. Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.
Traub-Weidinger T; Von Guggenberg E; Dobrozemsky G; Kendler D; Eisterer W; Bale R; Putzer D; Gabriel M; Virgolini I
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):52-60. PubMed ID: 20168286
[TBL] [Abstract][Full Text] [Related]
37. Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using
Ilan E; Velikyan I; Sandström M; Sundin A; Lubberink M
J Nucl Med; 2020 Feb; 61(2):217-221. PubMed ID: 31302632
[TBL] [Abstract][Full Text] [Related]
38. Blood mRNA Measurement (NETest) for Neuroendocrine Tumor Diagnosis of Image-Negative Liver Metastatic Disease.
Malczewska A; Bodei L; Kidd M; Modlin IM
J Clin Endocrinol Metab; 2019 Mar; 104(3):867-872. PubMed ID: 30358858
[TBL] [Abstract][Full Text] [Related]
39. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors.
Abdulrezzak U; Kurt YK; Kula M; Tutus A
Nucl Med Commun; 2016 Aug; 37(8):874-81. PubMed ID: 27096719
[TBL] [Abstract][Full Text] [Related]
40. Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China.
Liu M; Cheng Y; Bai C; Zhao H; Jia R; Chen J; Zhu W; Huo L
Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2002-2011. PubMed ID: 38337073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]